Ocular Diseases

Intrexon through collaboration is developing controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.  Through application of the Company’s RheoSwitch Therapeutic System® (RTS®) platform, a clinically validated method for controlling the location, concentration and timing of protein expression, the program looks to overcome a long-standing limitation of current approaches by enabling patients to receive a targeted biologic therapy without having to endure a lifetime of injections.
 
The initial target for this targeted biologic therapy is wet age-related macular degeneration (AMD), and other ocular diseases that are in focus include glaucoma and retinitis pigmentosa.